← Back to Screener
MiNK Therapeutics, Inc. Common Stock (INKT)
Price$12.38
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-3.80%
Price vs S&P 500 (4W)0.11%
VGM Score71.77
Market Capitalization$60.78M
All Metrics
Book Value / Share (Quarterly)$0.20
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.27
Price vs S&P 500 (YTD)-1.52%
EPS (TTM)$-2.84
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-2.84
EPS (Annual)$-0.65
ROI (Annual)-127.04%
Cash / Share (Quarterly)$1.92
ROA (Last FY)-493.33%
EBITD / Share (TTM)$-2.83
Cash Flow / Share (Annual)$-1.26
P/B Ratio9.00x
P/B Ratio (Quarterly)10.56x
Net Income / Employee (Annual)$-1,497,200
Net Interest Coverage (TTM)-1.40x
ROA (TTM)-118.58%
EPS Incl Extra (Annual)$-0.65
Current Ratio (Annual)1.06x
Quick Ratio (Quarterly)1.34x
3-Month Avg Trading Volume0.22M
52-Week Price Return75.29%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.39
P/S Ratio (Annual)88.09x
Asset Turnover (Annual)0.53x
52-Week High$76.00
EPS Excl Extra (Annual)$-0.65
26-Week Price Return12.13%
Quick Ratio (Annual)1.04x
13-Week Price Return10.61%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.38x
Enterprise Value$51.25M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3449.28%
Cash / Share (Annual)$2.84
3-Month Return Std Dev110.90%
Net Income / Employee (TTM)$-831,300
ROE (Last FY)-127.04%
EPS Basic Excl Extra (Annual)$-0.65
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.84
ROI (TTM)-168.87%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.01
Price vs S&P 500 (52W)47.08%
Year-to-Date Return9.42%
5-Day Price Return12.24%
EPS Normalized (Annual)$-0.65
ROA (5Y Avg)-574.34%
Net Profit Margin (Annual)-3449.28%
Month-to-Date Return0.00%
Cash Flow / Share (TTM)$-0.72
EBITD / Share (Annual)$-0.66
Operating Margin (Annual)-3228.99%
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.84
P/B Ratio (Annual)6.29x
Book Value / Share (Annual)$0.71
Price vs S&P 500 (13W)0.86%
Beta0.50x
Revenue / Share (TTM)$0.00
ROE (TTM)-168.87%
52-Week Low$6.80
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.57est. -0.79
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.13
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
INKTMiNK Therapeutics, Inc. Common Stock | — | — | B | $12.38 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its manufacturing platform enables scalable production of off-the-shelf cell therapies, with a pipeline of native and engineered iNKT programs.